Thomas Malley - 03 Jun 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Reporting relationship: Director
Issuer ticker: KNSA
Reported as of: 03 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2025, 17:02:16 UTC
Prior SEC filing: 07 Jun 2024
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Madelyn Zeylikman, Attorney-in-Fact

Key filing fact

Thomas Malley filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 05 Jun 2025.

Key facts

This page summarizes Thomas Malley's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 05 Jun 2025, 17:02.

Change

Previous filing in this sequence was filed on 07 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001403322 Primary reporting owner

Malley Thomas

Relationship: Director
Address: 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Signature date: 05 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNSA transaction

Class A Ordinary Shares

Options Exercise

Transaction value
Shares: +3,173
Change %: +34%
Price
Shares after: 12,546
Date: 05 Jun 2025
Ownership: Direct
Footnotes: F1

KNSA holding

Class A Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 71,967
Date: 03 Jun 2025
Ownership: See footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Share Option

Award

Transaction value: $0
Shares: +16,798
Change %
Price: $0.000000
Shares after: 16,798
Date: 03 Jun 2025
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 16,798
Exercise price: $29.11
Footnotes: F3

KNSA transaction Derivative

Restricted Share Units

Award

Transaction value: $0
Shares: +2,799
Change %
Price: $0.000000
Shares after: 2,799
Date: 03 Jun 2025
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 2,799
Exercise price
Footnotes: F1, F4

KNSA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value: $0
Shares: -3,173
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 3,173
Exercise price
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Footnote F2

Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock.

Footnote F3

The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

Footnote F4

The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

Footnote F5

The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs.